Brazilian journal of anesthesiology (Elsevier) · 2020
[Neurokinin-1 receptor antagonists for postoperative nausea and vomiting: a systematic review and meta-analysis].
Сравнительное исследованиеСтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Murakami Chiaki, Kakuta Nami, Satomi Shiho, Nakamura Ryuji, Miyoshi Hirotsugu, Morio Atsushi, Saeki Noboru, Kato Takahiro, Ohshita Naohiro, Tanaka Katsuya, Tsutsumi Yasuo M
Аннотация
BACKGROUND: Postoperative Nausea and Vomiting (PONV) is a common complication of general anesthesia. Several kinds of antiemetics, including 5-Hydroxytryptamine3 (5-HT3) receptor antagonists, and Neurokinin-1 (NK-1) receptor antagonists have been used to treat PONV.
OBJECTIVES: To compare the antiemetic effect of NK-1 receptor antagonists, including fosaprepitant.
DATA SOURCES: Online databases (PubMed, MEDLINE, Scopus, The Cochrane Library databases) were used.
STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS: Randomized Controlled Trials (RCTs) performed in patients over 18 years with ASA-PS of I‒III, aimed to assess the efficacy of antiemetics including NK-1 receptor antagonists and 5-HT3 receptor antagonists, and compared the incidence of PONV were included.
STUDY APPRAISAL AND SYNTHESIS METHODS: All statistical assessments were conducted by a random effect approach, and odds ratios and 95% Confidence Intervals were calculated.
RESULTS: Aprepitant 40 mg and 80 mg significantly reduced the incidence of vomiting 0‒24 hours postoperatively (Odds Ratio [OR = 0.40]; 95% Confidence Interval [95% CI 0.30‒0.54]; p < 0.001, and OR = 0.32; 95% CI 0.19‒0.56; p < 0.001). Fosaprepitant could also reduce the incidence of vomiting significantly both 0‒24 and 0‒48 hours postoperatively (OR = 0.07; 95% CI 0.02‒0.24; p < 0.001 and OR = 0.07; 95% CI 0.02‒0.23; p < 0.001).
LIMITATIONS: Risk factors for PONV are not considered, RCTs using multiple antiemetics are included, RCTs for fosaprepitant is small, and some bias may be present.
CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS: Aprepitant and fosaprepitant can be effective prophylactic antiemetics for postoperative vomiting. However, more studies are required for higher-quality meta-analyses.
SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42019120188.
OBJECTIVES: To compare the antiemetic effect of NK-1 receptor antagonists, including fosaprepitant.
DATA SOURCES: Online databases (PubMed, MEDLINE, Scopus, The Cochrane Library databases) were used.
STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS: Randomized Controlled Trials (RCTs) performed in patients over 18 years with ASA-PS of I‒III, aimed to assess the efficacy of antiemetics including NK-1 receptor antagonists and 5-HT3 receptor antagonists, and compared the incidence of PONV were included.
STUDY APPRAISAL AND SYNTHESIS METHODS: All statistical assessments were conducted by a random effect approach, and odds ratios and 95% Confidence Intervals were calculated.
RESULTS: Aprepitant 40 mg and 80 mg significantly reduced the incidence of vomiting 0‒24 hours postoperatively (Odds Ratio [OR = 0.40]; 95% Confidence Interval [95% CI 0.30‒0.54]; p < 0.001, and OR = 0.32; 95% CI 0.19‒0.56; p < 0.001). Fosaprepitant could also reduce the incidence of vomiting significantly both 0‒24 and 0‒48 hours postoperatively (OR = 0.07; 95% CI 0.02‒0.24; p < 0.001 and OR = 0.07; 95% CI 0.02‒0.23; p < 0.001).
LIMITATIONS: Risk factors for PONV are not considered, RCTs using multiple antiemetics are included, RCTs for fosaprepitant is small, and some bias may be present.
CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS: Aprepitant and fosaprepitant can be effective prophylactic antiemetics for postoperative vomiting. However, more studies are required for higher-quality meta-analyses.
SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42019120188.